孟加拉国无死亡COVID-19患者的现实生活管理策略:一项观察性和队列研究

Akm Faizul Huq, Md Fashiur Rahman, Md Azizul Islam, Syed A Iqbal, Azizur Rahman, Syed Abul Hassan Md Abdullah, Mamun Al Mahtab, Sheikh Mf Akbar
{"title":"孟加拉国无死亡COVID-19患者的现实生活管理策略:一项观察性和队列研究","authors":"Akm Faizul Huq,&nbsp;Md Fashiur Rahman,&nbsp;Md Azizul Islam,&nbsp;Syed A Iqbal,&nbsp;Azizur Rahman,&nbsp;Syed Abul Hassan Md Abdullah,&nbsp;Mamun Al Mahtab,&nbsp;Sheikh Mf Akbar","doi":"10.5005/jp-journals-10018-1316","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared as pandemic by World Health Organization (WHO) with increasing morbidity (more than 4.6 million patients) and mortality (300,000 deaths). The world-wide target of management COVID-19 is to reduce complications with available management options; this become highly variable from country to country and even within different regions of the same country.</p><p><strong>Aim and objective: </strong>This observational prospective study represents a single center study in which all patients in this cohort received almost similar medicines and care.</p><p><strong>Materials and methods: </strong>All patients in this cohort (<i>N</i>: 32) were positive for SARS-CoV-2 by polymerase chain reaction (PCR) with variable presenting symptoms. The management strategy included Standard of Care (SoC) and administration of hydroxychloroquine and doxycycline. Out of 32 patients, 9 patients also received favipiravir. All patients were followed until they were discharged after negativity of SARS-CoV-2 confirmed by PCR on two consecutive occasions taken within 2 days.</p><p><strong>Results: </strong>No death has been recorded in this cohort of 32 patients within the study period. The average hospital staying duration was 13.9 days with a range of 8-21 days. All patients were discharged with improvement of subjective symptoms and SARS-CoV-2 negativity. The vital signs (pulse, blood pressure) as well as and levels of electrolyte and blood counts were within normal and acceptable ranges at the time of discharge.</p><p><strong>Conclusion: </strong>The study presented here provide and evidence of a real-life situation of management of limited numbers of COVID-19 patients at a tertiary center of Bangladesh. This study inspires optimism that proper diagnosis, establishment of effective inclusion and exclusion criteria, ensuring application of proper SoC with drugs available in Bangladesh may be a practical option for management of COVID-19 in the country.</p><p><strong>How to cite this article: </strong>Huq AKMF, Rahman MF, Islam MA, <i>et al.</i> Real-life Management Strategy of COVID-19 Patients in Bangladesh with No Death: An Observational and Cohort Study. Euroasian J Hepato-Gastroenterol 2020;10(1):31-35.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"10 1","pages":"31-35"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cb/83/ejohg-10-31.PMC7376598.pdf","citationCount":"9","resultStr":"{\"title\":\"Real-life Management Strategy of COVID-19 Patients in Bangladesh with No Death: An Observational and Cohort Study.\",\"authors\":\"Akm Faizul Huq,&nbsp;Md Fashiur Rahman,&nbsp;Md Azizul Islam,&nbsp;Syed A Iqbal,&nbsp;Azizur Rahman,&nbsp;Syed Abul Hassan Md Abdullah,&nbsp;Mamun Al Mahtab,&nbsp;Sheikh Mf Akbar\",\"doi\":\"10.5005/jp-journals-10018-1316\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared as pandemic by World Health Organization (WHO) with increasing morbidity (more than 4.6 million patients) and mortality (300,000 deaths). The world-wide target of management COVID-19 is to reduce complications with available management options; this become highly variable from country to country and even within different regions of the same country.</p><p><strong>Aim and objective: </strong>This observational prospective study represents a single center study in which all patients in this cohort received almost similar medicines and care.</p><p><strong>Materials and methods: </strong>All patients in this cohort (<i>N</i>: 32) were positive for SARS-CoV-2 by polymerase chain reaction (PCR) with variable presenting symptoms. The management strategy included Standard of Care (SoC) and administration of hydroxychloroquine and doxycycline. Out of 32 patients, 9 patients also received favipiravir. All patients were followed until they were discharged after negativity of SARS-CoV-2 confirmed by PCR on two consecutive occasions taken within 2 days.</p><p><strong>Results: </strong>No death has been recorded in this cohort of 32 patients within the study period. The average hospital staying duration was 13.9 days with a range of 8-21 days. All patients were discharged with improvement of subjective symptoms and SARS-CoV-2 negativity. The vital signs (pulse, blood pressure) as well as and levels of electrolyte and blood counts were within normal and acceptable ranges at the time of discharge.</p><p><strong>Conclusion: </strong>The study presented here provide and evidence of a real-life situation of management of limited numbers of COVID-19 patients at a tertiary center of Bangladesh. This study inspires optimism that proper diagnosis, establishment of effective inclusion and exclusion criteria, ensuring application of proper SoC with drugs available in Bangladesh may be a practical option for management of COVID-19 in the country.</p><p><strong>How to cite this article: </strong>Huq AKMF, Rahman MF, Islam MA, <i>et al.</i> Real-life Management Strategy of COVID-19 Patients in Bangladesh with No Death: An Observational and Cohort Study. Euroasian J Hepato-Gastroenterol 2020;10(1):31-35.</p>\",\"PeriodicalId\":11992,\"journal\":{\"name\":\"Euroasian Journal of Hepato-Gastroenterology\",\"volume\":\"10 1\",\"pages\":\"31-35\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cb/83/ejohg-10-31.PMC7376598.pdf\",\"citationCount\":\"9\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Euroasian Journal of Hepato-Gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5005/jp-journals-10018-1316\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Euroasian Journal of Hepato-Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5005/jp-journals-10018-1316","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 9

摘要

背景:由严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)引起的冠状病毒病2019 (COVID-19)已被世界卫生组织(WHO)宣布为大流行,发病率(超过460万例)和死亡率(30万例死亡)不断增加。管理COVID-19的全球目标是利用现有的管理方案减少并发症;这在不同国家之间,甚至在同一个国家的不同地区,都有很大的差异。目的和目的:本观察性前瞻性研究是一项单中心研究,该队列中所有患者接受几乎相同的药物和护理。材料与方法:本组患者(N: 32)均为SARS-CoV-2聚合酶链反应(PCR)阳性,症状不同。管理策略包括护理标准(SoC)和给予羟氯喹和强力霉素。在32例患者中,9例患者也接受了favipiravir治疗。所有患者在2天内连续两次经PCR确诊为SARS-CoV-2阴性后随访至出院。结果:32例患者在研究期间无死亡记录。平均住院时间13.9天,8 ~ 21天不等。所有患者主观症状改善,SARS-CoV-2阴性出院。出院时的生命体征(脉搏、血压)、电解质水平和血细胞计数均在正常和可接受范围内。结论:本文提出的研究提供了孟加拉国三级中心对有限数量的COVID-19患者进行管理的现实情况和证据。这项研究使人们乐观地认为,适当的诊断、建立有效的纳入和排除标准、确保在孟加拉国现有药物的基础上使用适当的SoC,可能是该国管理COVID-19的一个切实可行的选择。如何引用本文:Huq AKMF, Rahman MF, Islam MA等。孟加拉国无死亡COVID-19患者的现实生活管理策略:一项观察性和队列研究中华肝病与胃肠病杂志[J]; 2010;10(1):31-35。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Real-life Management Strategy of COVID-19 Patients in Bangladesh with No Death: An Observational and Cohort Study.

Background: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared as pandemic by World Health Organization (WHO) with increasing morbidity (more than 4.6 million patients) and mortality (300,000 deaths). The world-wide target of management COVID-19 is to reduce complications with available management options; this become highly variable from country to country and even within different regions of the same country.

Aim and objective: This observational prospective study represents a single center study in which all patients in this cohort received almost similar medicines and care.

Materials and methods: All patients in this cohort (N: 32) were positive for SARS-CoV-2 by polymerase chain reaction (PCR) with variable presenting symptoms. The management strategy included Standard of Care (SoC) and administration of hydroxychloroquine and doxycycline. Out of 32 patients, 9 patients also received favipiravir. All patients were followed until they were discharged after negativity of SARS-CoV-2 confirmed by PCR on two consecutive occasions taken within 2 days.

Results: No death has been recorded in this cohort of 32 patients within the study period. The average hospital staying duration was 13.9 days with a range of 8-21 days. All patients were discharged with improvement of subjective symptoms and SARS-CoV-2 negativity. The vital signs (pulse, blood pressure) as well as and levels of electrolyte and blood counts were within normal and acceptable ranges at the time of discharge.

Conclusion: The study presented here provide and evidence of a real-life situation of management of limited numbers of COVID-19 patients at a tertiary center of Bangladesh. This study inspires optimism that proper diagnosis, establishment of effective inclusion and exclusion criteria, ensuring application of proper SoC with drugs available in Bangladesh may be a practical option for management of COVID-19 in the country.

How to cite this article: Huq AKMF, Rahman MF, Islam MA, et al. Real-life Management Strategy of COVID-19 Patients in Bangladesh with No Death: An Observational and Cohort Study. Euroasian J Hepato-Gastroenterol 2020;10(1):31-35.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Scientific Insights for Drug Development Based on Normal Habitat of Tribal Population of Manipur: An Observational Study Regarding the Implication of “Houttuynia cordata” Can the Inflammatory Cell Ratio NLR and PLR be Used as a Reliable Marker in Colon Cancer? A Prospective Study Memories of Professor HASAN Ozkan: Blowing in the Wind The Journal Moving to an Adult State The Hooking Technique for Retrograde Freehand Access during Direct Cholangioscopy (with Video).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1